Skip to main content
Feedback to SSRN
Feedback
(required)
Email
(required)
Submit
If you need immediate assistance, call 877-SSRNHelp (877 777 6435) in the United States, or +1 212 448 2500 outside of the United States, 8:30AM to 6:00PM U.S. Eastern, Monday - Friday.
Hans-Martin Schneble
Servier International Research Institute (IRIS)
France
Learn more about SSRN Profiles
SCHOLARLY PAPERS
1
DOWNLOADS
40
SSRN CITATIONS
0
CROSSREF CITATIONS
0
Feedback
Scholarly Papers (1)
Sort by:
Paper Title, A-Z
Paper Title, Z-A
Author Name, A-Z
Author Name, Z-A
Date Posted, Ascending
Date Posted, Descending
Downloads, Ascending
Downloads, Descending
Citations, Ascending
Citations, Descending
Actions:
Email selected abstracts
View:
Selected
Original List
All Versions
Hide All Versions
All Abstracts
Hide All Abstracts
(Rank)
1.
Efficacy and Safety of Temelimab, an Antibody Antagonist of the Human Endogenous Retrovirus Type-W env Protein, in Participants with Relapsing Remitting Multiple Sclerosis: A Double-Blind, Randomised, Placebo-Controlled Phase 2b Clinical Trial
Number of pages: 130
Posted: 17 May 2019
Hans-Peter Hartung
,
Tobias Derfuss
,
Bruce Cree
,
Maria Pia Sormani
,
Krzysztof Selmaj
,
Jon Stutters
,
Ferran Prados
,
David MacManus
, Hans-Martin Schneble,
Hervé Porchet
,
Robert Glanzman
,
Estelle Lambert
,
Gordon Francis
,
Francois Curtin
and
Frederik Barkhof
Heinrich Heine University Dusseldorf - Department of Neurology, University of Basel - University Hospital Basel, University of California, San Francisco (UCSF) - Weill Institute for Neurosciences, Department of Health Sciences (DISSAL), Medical University of Lodz, University College London - Institute of Neurology, University College London - Institute of Neurology, University College London - Institute of Neurology, Servier International Research Institute (IRIS), GeNeuro SA, GeNeuro SA, Servier International Research Institute (IRIS), GeNeuro SA, GeNeuro SA and VU University Amsterdam - Neuroscience Campus Amsterdam
Downloads
40
(502,689)
View PDF
Download
Abstract:
Multiple sclerosis; HERV-directed temelimab; phase 2 trial; neuroprotection
Feedback